Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail and Poster Display session

10P - Treatment of vaginal cancer by suppression of inhibitory receptors of CD8 T cell in mouse model

Date

26 Feb 2024

Session

Cocktail and Poster Display session

Topics

Immunotherapy

Tumour Site

Vulvar and Vaginal Cancers

Presenters

Dong Choon Park

Citation

Annals of Oncology (2024) 9 (suppl_1): 1-5. 10.1016/esmoop/esmoop102260

Authors

D.C. Park1, J.H. Yeo2, J. Yun3, S.G. Yeo4, S. Lee5

Author affiliations

  • 1 Gynecologic Oncology, The Catholic University of Korea - St. Vincent's Hospital, 442-723 - Suwon/KR
  • 2 Health Care, Public Health Center, Danyang-gun, Chungcheongbuk-do, Republic of Korea, 27010 - Danyang/KR
  • 3 Obstetrics And Gynecology Department, The Catholic University of Korea - St. Vincent's Hospital, 442-723 - Suwon/KR
  • 4 Otorhinolaryngology, Head & Neck Surgery, Kyung Hee University Hospital, 130-702 - Seoul/KR
  • 5 Obstetrics And Gynecology Department, The Catholic University of Korea - Seoul St. Mary's Hospital - Catholic Medical Center, 137-701 - Seoul/KR

Resources

This content is available to ESMO members and event participants.

Abstract 10P

Background

Activation of exhausted CD8 T cell and migration of immune cells into tumor site is an important for overcoming resistance to cancer therapy. We evaluated the role of suppression of inhibitory receptors and chemokine axis in vaginal tumor bearing mouse.

Methods

C57BL/6 mice were categorized into four groups according to treatment modality. Mice were challenged with 1×105 TC-1 cells on vagina. HPV DNA therapeutic vaccine was injected intramuscularly and intratumoral injection of GMCSF was performed. The mice were harvested on day 21 and immune cells were investigated by flow cytometry. We checked the expression of inhibitory receptors of CD8 T cells, including PD1, TIM3 and LAG3. Chemokine axis such as CXCL9, CXCL10, and CXCR3 were evaluated to know migration mechanism.

Results

Combination of HPV DNA vaccine and GMCSF resulted in significantly lower expression of TIM3 inhibitory receptors of CD8+ T cells in tumor (p<0.05). However, expression level of PD1 and LAG3 was not changed after combination therapy. They significantly induced accumulation of tumor specific CD8 T cell in tumor site and increased expression of CXCR3 on tumor infiltration CD8 T cell (p<0.05). CXCL9, chemokine, was overexpressed in vaginal tumor after combination therapy (p<0.05). However, expression level of CXCL10 was not changed after combination therapy. Finally, mice treated with combination therapy survived significantly longer than other groups with single therapy (p<0.05).

Conclusions

In conclusion, we overcame T cell exhaustion and identified chemokine axis during migration of CD8 T cell into vaginal tumor using HPV DNA vaccine and GMCSF. This mechanism can be ideal target for future immunotherapy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.